Dissocia？？o da resposta anti-hipertensiva e metabólica à losartana e espironolactona em ratos com síndrome metabólica experimental

introduction: the treatment of arterial hypertension (ah) in patients with metabolic syndrome (ms) is a challenge, since non drug therapies are difficult to implement and optimal pharmacological treatment is not fully established. objective: to assess the blockade of the rennin angiotensin aldosterone system (raas) in blood pressure (bp) in renal function and morphology in an experimental model of ms induced by high fat diet. methods: wistar rats were fed on high fat diet from the fourth week of life, for 20 weeks. the groups received losartan or spironolactone from the eighth week of life. we weekly evaluated the body weight and bp by tail plethysmography. at the end of the experiment oral glucose tolerance, lipid profile, creatinine clearance tests, and the direct measurement of bp were performed. a morphometric kidney analysis was performed. results: the administration of high-fat diet was associated with the development of ms, characterized by central fat accumulation, hypertension, hyperglycemia and hypertriglyceridemia. in this model there were no changes in renal histomorphometry. the blockade of angiotensin ii (ang ii) receptor at1 prevented the development of hypertension. the mineralocorticoid blockage did not have antihypertensive efficacy but was associated with reduction of abdominal fat. conclusion: the dissociation of the antihypertensive response to the blockades of ang ii receptors and mineralocorticoid indicates the involvement of ang ii in the pathogenesis of hypertension associated with obesity. reduction of central obesity with spironolactone suggests the presence of mineralocorticoid adipogenic effect.